After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?

2007 ◽  
Vol 7 (4) ◽  
pp. 409-416 ◽  
Author(s):  
Zili Zhang ◽  
David J. Hinrichs ◽  
Huiying Lu ◽  
Hong Chen ◽  
Wenwei Zhong ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Targets ◽  
Interleukin 17 ◽  
Inflammatory Bowel ◽  
Interleukin 23

scholarly journals Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets

2013 ◽  
Vol 19 (14) ◽  
pp. 1711-1747 ◽  
Author(s):  
Fiorella Biasi ◽  
Gabriella Leonarduzzi ◽  
Patricia I. Oteiza ◽  
Giuseppe Poli
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Targets ◽  
Disease Mechanisms ◽  
Inflammatory Bowel

scholarly journals Hydroxylases as therapeutic targets in inflammatory bowel disease

2013 ◽  
Vol 93 (4) ◽  
pp. 378-383 ◽  
Author(s):  
Eoin P Cummins ◽  
Glen A Doherty ◽  
Cormac T Taylor
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Targets ◽  
Inflammatory Bowel

scholarly journals The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease

2010 ◽  
Vol 160 (3) ◽  
pp. 386-393 ◽  
Author(s):  
T. Sugihara ◽  
A. Kobori ◽  
H. Imaeda ◽  
T. Tsujikawa ◽  
K. Amagase ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Complement C3 ◽  
Interleukin 17 ◽  
Inflammatory Bowel

scholarly journals Replication of interleukin 23 receptor and autophagyrelated 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy

2008 ◽  
Vol 14 (29) ◽  
pp. 4643 ◽  
Author(s):  
Anna Latiano ◽  
Orazio Palmieri ◽  
Maria Rosa Valvano ◽  
Renata D’Incà ◽  
Salvatore Cucchiara ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Interleukin 23 ◽  
Pediatric Onset

scholarly journals Psoriasis and Inflammatory Bowel Disease

2019 ◽  
Vol 37 (6) ◽  
pp. 451-457 ◽  
Author(s):  
Mario Cottone ◽  
Chiara Sapienza ◽  
Fabio Salvatore Macaluso ◽  
Marco Cannizzaro
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Immunological Mechanisms ◽  
Predisposition Genes ◽  
Associated Conditions ◽  
Inflammatory Bowel ◽  
Interleukin 23 ◽  
Risk Of Cancer ◽  
Similar Risk ◽  
Necrosis Factor

Background: Inflammatory bowel disease (IBD) and psoriasis (PS) are associated conditions. The reason for this association lies in the sharing of predisposition genes and common immunological mechanisms. Summary: This review will focus on the interplay between IBD and PS, with details on prevalence and phenotype of PS in IBD, genetics, pathogenetic pathways, and therapy. Key Messages: Microbiome seems relevant in both conditions: a reduction of beneficial bacteria has been observed. IBD and PS have in common some comorbidities like cardiovascular disease, similar risk of cancer and psychiatric problems. Many biological therapies such as anti-tumour necrosis factor (TNF) and anti-interleukin 23 are effective in both conditions, underlining the common immunological mechanisms. Paradoxical PS has been mainly observed after anti-TNF therapies, but preliminary reports show that it can also occur with other biologics. Genetic predisposition to this phenomenon has been reported.

Sign in / Sign up

Export Citation Format

Share Document